Transient EZH2 suppression by Tazemetostat during in vitro expansion maintains T cell stemness and improves adoptive T cell therapy
Y. Hou, J. Zak, Y. Shi, I. Pratumchai, B. Dinner, W. Wang, K. Qin, E. W. Weber, J. Teijaro, P. Wu
The paper shows that transient EZH2 inhibition with Tazemetostat during T cell expansion maintains stemness and improves adoptive T cell therapy outcomes in a murine model.
bioRxiv · Feb 7, 2023 · PreprintImmunology